company background image
INFI

Infinity Pharmaceuticals NasdaqGS:INFI Stock Report

Last Price

US$1.15

Market Cap

US$102.5m

7D

43.8%

1Y

-62.9%

Updated

12 Aug, 2022

Data

Company Financials +
INFI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

INFI Stock Overview

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.

Infinity Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Infinity Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.15
52 Week HighUS$3.89
52 Week LowUS$0.46
Beta2
1 Month Change75.57%
3 Month Change114.03%
1 Year Change-62.90%
3 Year Change-5.74%
5 Year Change15.00%
Change since IPO-92.58%

Recent News & Updates

May 23
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

INFIUS BiotechsUS Market
7D43.8%1.2%3.2%
1Y-62.9%-21.7%-10.1%

Return vs Industry: INFI underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: INFI underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is INFI's price volatile compared to industry and market?
INFI volatility
INFI Average Weekly Movement19.8%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: INFI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: INFI's weekly volatility has increased from 14% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199523Adelene Perkinshttps://www.infi.com

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Infinity Pharmaceuticals, Inc. Fundamentals Summary

How do Infinity Pharmaceuticals's earnings and revenue compare to its market cap?
INFI fundamental statistics
Market CapUS$102.53m
Earnings (TTM)-US$46.79m
Revenue (TTM)US$2.22m

46.3x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INFI income statement (TTM)
RevenueUS$2.22m
Cost of RevenueUS$32.98m
Gross Profit-US$30.77m
Other ExpensesUS$16.02m
Earnings-US$46.79m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin-1,387.78%
Net Profit Margin-2,110.33%
Debt/Equity Ratio0%

How did INFI perform over the long term?

See historical performance and comparison